Skin Cancer

Unloxcyt was approved by the FDA as a new treatment for patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

The FDA approved several drugs throughout November for the treatment of diseases including leukemia and biliary tract cancer, in addition to a diagnostic for solid cancers.

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.

Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in early data from a phase 3 trial.

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.

From Jenna Fischer announcing her breast cancer diagnosis to Martha Davis and the Motels canceling concerts after her radiation therapy, here’s what’s happening in the cancer space this week.

Among patients with Merkel cell carcinoma, using ctDNA testing may help with watching the disease for potential recurrences and those who are high-risk.

An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

The Food and Drug Administration granted a fast track designation to IBI363 for patients with unresectable advanced or metastatic melanoma.

A new algorithm has found that combining immune checkpoint inhibitors bolsters immune response among some patients with advanced melanoma.

Health-related quality of life among patients with stage 3 melanoma was not significantly affected after receiving postsurgical Keytruda or placebo.

The cancer vaccine, mRNA-4157, garnered immune responses of 30 weeks among some patients with melanoma and lung cancer, study results showed.

From “Top Chef’” Shirley Chung and comedian Christina Pazsitzky announcing their diagnoses to Erica Ash’s death from the disease, here is what’s happening in the oncology space this week.

We asked oncology experts what questions patients should ask their doctors soon after receiving a cancer diagnosis. This is their advice.

Researchers have found that among patients with certain melanoma, presurgical targeted therapy and immunotherapy can result in better pathologic response.

Citing toxicities and lack of efficacy, some are calling for caution when treating older patients with melanoma with immune checkpoint inhibitors.

From Teddi Mellencamp revealing that she had more melanoma spots removed to Isabella Strahan announcing being cancer-free, here’s what’s happening in the oncology space this week.

The TIL therapy OBX-115 ‘may have the potential to address’ an unmet need among patients with metastatic or locally advanced melanoma.

Perioperative treatment with BRAF and MEK inhibitors was found to benefit some patients with stage 3 and 4 melanoma, according to a recent study.

From the lead singer of Heart’s cancer diagnosis and postponing their tour to Dick Vitale’s upcoming cancer surgery, here’s what’s going on in the cancer space this week.

Following promising European trial results, a new peptide vaccine for melanoma is being studied in America, with results expected next year.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

Are cancer vaccines the new frontier in oncology? Experts and patients weigh in from the front lines.

From Kate Middleton giving an update on her cancer treatment to Kevin Jonas’ skin cancer surgery, here’s what’s happening in the oncology space this week.

Learning that I had cancer — melanoma and renal cell carcinoma — made me feel like I lost something, but I keep looking ahead.

Opdivo plus Yervoy in the neoadjuvant setting reduced the risk for recurrence, progression or death, potentially offering patients with stage 3 melanoma a new standard of care.

Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.